|
1
|
GBD 2023 Breast Cancer Collaborators, .
Global, regional, and national burden of breast cancer among
females, 1990–2023, with forecasts to 2050: A systematic analysis
for the global burden of disease study 2023. Lancet Oncol.
27:302–326. 2026. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tan C, Xie G, Wu S, Song C, Zhang J, Yi X,
Wang J and Tang H: Simultaneous detection of breast cancer
biomarkers circROBO1 and BRCA1 based on a CRISPR-Cas13a/Cas12a
system. Biosens Bioelectron. 258:1163732024. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Xie X, Chen C, Wang C, Guo Y, Sun B, Tian
J, Yan J, Li D and Chen G: Targeting GPX4-mediated ferroptosis
protection sensitizes BRCA1-deficient cancer cells to PARP
inhibitors. Redox Biol. 76:1033502024. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bowen CM, Demarest K, Vilar E and Shah PD:
Novel cancer prevention strategies in individuals with hereditary
cancer syndromes: Focus on BRCA1, BRCA2, and lynch syndrome. Am Soc
Clin Oncol Educ Book. 44:e4335762024. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Eras N, Tuncel F, Altintas Z and Erden S:
Clinicopathological characteristics and BRCA1/BRCA2 pathogenic
variants of patients with breast cancer. Pol J Pathol. 75:1–7.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Metcalfe K, Huzarski T, Gronwald J,
Kotsopoulos J, Kim R, Moller P, Pal T, Aeilts A, Eisen A, Karlan B,
et al: Risk-reducing mastectomy and breast cancer mortality in
women with a BRCA1 or BRCA2 pathogenic variant: An international
analysis. Br J Cancer. 130:269–274. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Record SM, Thomas SM, Ntowe K, Chiba A and
Plichta JK: BRCA1/2 mutation carriers & risk reducing
mastectomy: Who undergoes surgery and potential benefits. Am J
Surg. 227:146–152. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Schwartz M, Ibadioune S, Chansavang A,
Vacher S, Caputo SM, Delhomelle H, Wong J, Abidallah K, Moncoutier
V, Becette V, et al: Mosaic BRCA1 promoter methylation contribution
in hereditary breast/ovarian cancer pedigrees. J Med Genet.
61:284–288. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Innella G, Fortuno C, Caleca L, Feng BJ,
Carroll C, Parsons MT, Miccoli S, Montagna M, Calistri D, Cortesi
L, et al: Atypical cancer risk profile in carriers of Italian
founder BRCA1 variant p.His1673del: Implications for classification
and clinical management. Cancer Med. 13:e701142024. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ning Y, Zhang Y, Tian T, Chen Y, Wang J,
Lei K and Cui Z: Reclassifying BRCA1 c.4358-2A > G and BRCA2
c.475 + 5G > Cvariants from ‘uncertain significance’ to
‘pathogenic’ based on minigene assays and clinical evidence. J
Cancer Res Clin Oncol. 150:622024. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sokolenko AP, Bakaeva EK, Venina AR,
Kuligina ES, Romanko AA, Aleksakhina SN, Belysheva YV, Belogubova
EV, Stepanov IA, Zaitseva OA, et al: Ethnicity-specific BRCA1,
BRCA2, PALB2, and ATM pathogenic alleles in breast and ovarian
cancer patients from the North Caucasus. Breast Cancer Res Treat.
203:307–315. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wu Z, Zhang Q, Jin Y, Zhang X, Chen Y,
Yang C, Tang X, Jiang H, Wang X, Zhou X, et al: Population-based
BRCA germline mutation screening in the Han Chinese identifies
individuals at risk of BRCA mutation-related cancer: Experience
from a clinical diagnostic center from greater Shanghai area. BMC
Cancer. 24:4112024. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dell'Edera D, Allegretti A, La Rocca F,
Centoducati C and Persia B: A novel BRCA2 pathogenic variant
c.7094_7100del (p.His2365LeufsTer9) in an Italian family with
hereditary breast cancer. Eur Rev Med Pharmacol Sci. 28:1178–1182.
2024.PubMed/NCBI
|
|
14
|
de Oliveira Ferreira C, Carneiro VCG and
Araujo Mariz C: Germline mutations in BRCA1 and BRCA2 among
Brazilian women with ovarian cancer treated in the public health
system. BMC Cancer. 24:4992024. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yang X, Shang L, Yang L, Sun L, Tuo X, Ma
S, Zhao L, Li X and Yang W: A novel germline mutation of BRCA1 and
integrated analysis with somatic mutation in a Chinese multi-cancer
family. Oncologist. 29:e837–e842. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kurihara C, Kerpel-Fronius S, Becker S,
Chan A, Nagaty Y, Naseem S, Schenk J, Matsuyama K and Baroutsou V:
Declaration of Helsinki: Ethical norm in pursuit of common global
goals. Front Med (Lausanne). 11:13606532024. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wolff AC, Somerfield MR, Dowsett M,
Hammond MEH, Hayes DF, McShane LM, Saphner TJ, Spears PA and
Allison KH: Human epidermal growth factor receptor 2 testing in
breast cancer: ASCO-college of American pathologists guideline
update. J Clin Oncol. 41:3867–3872. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gradishar WJ, Moran MS, Abraham J, Aft R,
Agnese D, Allison KH, Anderson B, Burstein HJ, Chew H, Dang C, et
al: Breast cancer, version 3.2022, NCCN clinical practice
guidelines in oncology. J Natl Compr Canc Netw. 20:691–722. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
McCluggage WG, Singh N and Gilks CB: Key
changes to the World Health Organization (WHO) classification of
female genital tumours introduced in the 5th edition (2020).
Histopathology. 80:762–778. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Richards S, Aziz N, Bale S, Bick D, Das S,
Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, et al:
Standards and guidelines for the interpretation of sequence
variants: A joint consensus recommendation of the American college
of medical genetics and genomics and the association for molecular
pathology. Genet Med. 17:405–424. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wolff AC, Hammond MEH, Allison KH, Harvey
BE, Mangu PB, Bartlett JMS, Bilous M, Ellis IO, Fitzgibbons P,
Hanna W, et al: Human epidermal growth factor receptor 2 testing in
breast cancer: American society of clinical oncology/college of
American pathologists clinical practice guideline focused update. J
Clin Oncol. 36:2105–2122. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ivanova M, Porta FM, D'Ercole M, Pescia C,
Sajjadi E, Cursano G, De Camilli E, Pala O, Mazzarol G, Venetis K,
et al: Standardized pathology report for HER2 testing in compliance
with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on
HER2-low breast cancer. Virchows Arch. 484:3–14. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xu L, Ye JM, Zhu SN, Zhao JY, Xin L, Cheng
YJ, Liu Q, Zhang H, Zhang S, Duan XN and Liu YH: Analysis of
neoadjuvant docetaxel, carboplatin and trastuzumab (TCH) in
HER-2-positive breast cancer. Zhonghua Yi Xue Za Zhi. 98:907–911.
2018.(In Chinese). PubMed/NCBI
|
|
24
|
Miglietta F, Ragazzi M, Fernandes B,
Griguolo G, Massa D, Girardi F, Bottosso M, Bisagni A, Zarrilli G,
Porra F, et al: A prognostic model based on residual cancer burden
and tumor-infiltrating lymphocytes on residual disease after
neoadjuvant therapy in HER2+ breast cancer. Clin Cancer Res.
29:3429–3437. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kizildag Yirgin I, Has D, Arslan G, Aydin
EC, Sari M, Onder S, Yasemin S, Cabioglu N, Karanlik H, Tukenmez M,
et al: Comparison between body composition parameters and response
to neoadjuvant chemotherapy by using pre-treatment PET CT in
locally advanced breast cancer. Eur J Radiol Open. 7:1002862020.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Andrikopoulou A, Zografos E, Apostolidou
K, Kyriazoglou A, Papatheodoridi AM, Kaparelou M, Koutsoukos K,
Liontos M, Dimopoulos MA and Zagouri F: Germline and somatic
variants in ovarian carcinoma: A next-generation sequencing (NGS)
analysis. Front Oncol. 12:10307862022. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shirota H, Miyake A, Kawamura M, Suzuki S,
Saito K, Yasuda J, Shibata H, Saito M, Iwaya T, Tada H, et al:
Regional differences in the frequency of BRCA1 and BRCA2 variants
in northeastern Japan: A cohort study. Cancer Med. 14:e704432025.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Alés-Martínez JE, Balmaña J,
Sánchez-Rovira P, Salvador Bofill FJ, García Sáenz JÁ, Pimentel I,
Morales S, Fernández-Abad M, Lahuerta Martínez A, Ferrer N, et al:
Olaparib plus trastuzumab in HER2-positive advanced breast cancer
patients with germline BRCA1/2 mutations: The OPHELIA phase 2
study. Breast. 77:1037802024. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Moukha-Chafiq O, Boohaker R, Bratton LD,
Yatchang MF, Vadukoot AK, Sarngadharan S and Augelli-Szafran C:
Discovery of a novel non-toxic analog of clofarabine for the
treatment of triple-negative breast cancer. Bioorg Med Chem Lett.
128:1303492025. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Labidi-Galy SI, Rodrigues M, Sandoval JL,
Kurtz JE, Heitz F, Mosconi AM, Romero I, Denison U, Nagao S,
Vergote I, et al: Association of location of BRCA1 and BRCA2
mutations with benefit from olaparib and bevacizumab maintenance in
high-grade ovarian cancer: Phase III PAOLA-1/ENGOT-ov25 trial
subgroup exploratory analysis. Ann Oncol. 34:152–162. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wen S, Zhang M, Chen J, Hu L, Sun J, Yao
L, Xu Y, Zhang J and Xie Y: Characteristics of Chinese breast
cancer patients with double heterozygosity for BRCA1 and BRCA2
germline pathogenic variants. Breast Cancer Res Treat. 208:155–164.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Pan L, Shi C, Choi J and Lin J: IL-6
blockade enhances the efficacy of CDK4/6 inhibitor in BRCA1-mutant
triple-negative breast cancer cells. Cells. 14:16022025. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Nakamura Y, Nishimura-Yano Y, Nishimura M,
Kokubo T, Daino K, Takabatake M, Nagata K, Mashimo T, Kakinuma S,
Inoue K and Imaoka T: Spontaneous and radiation-induced mammary and
thyroid tumorigenesis in LEW and (SDxCOP)F1 Brca1 L63X/+
rats. Anticancer Res. 45:4869–4880. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kaseki S, Sonehara R, Motooka Y, Tanaka H,
Nakamura T, Osuka S, Akatsuka S, Kajiyama H, Mashimo T, Imaoka T
and Toyokuni S: Susceptibility of Brca1(L63X/+) rat to
ovarian reserve dissipation by chemotherapeutic agents to breast
cancer. Cancer Sci. 116:1139–1152. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cortes-Salgado A, Serrano JJ, Cordero
Pereda D, Menacho M, Del Rey JM, Del Campo-Albendea L, Saavedra C,
Chamorro J, Rosero D, Sotoca P, et al: Anthracyclines-induced
cardiotoxicity in patients with early breast cancer carrying
germline BRCA1/2 mutation: The BRCAN study. Oncologist.
30:oyae2992025. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lin B, LeVee A, Cao L, Basho R, Tamarappoo
B, Wei J and Shufelt C: Left ventricular global longitudinal strain
is worse in BRCA mutation positive breast cancer patients prior to
cancer treatment and premature menopause. Breast Cancer Res Treat.
207:103–109. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Radecka B and Litwiniuk M: Breast cancer
in young women. Ginekol Pol. 87:659–663. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Botty van den Bruele A, Ren Y, Thomas SM,
Ntowe KW, Rosenberger LH, Menendez C, Grimm LJ, Chiba A and Plichta
JK: High risk surveillance MRI may not be necessary in BRCA1/2
mutation carriers over 70 years old. Breast Cancer Res Treat.
211:421–429. 2025. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Stjepanovic N, Lubinski J, Moller P,
Randall Armel S, Foulkes WD, Tung N, Neuhausen SL, Kotsopoulos J,
Sun P, Sun S, et al: Breast cancer risk after age 60 among BRCA1
and BRCA2 mutation carriers. Breast Cancer Res Treat. 187:515–523.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sopik V, Phelan C, Cybulski C and Narod
SA: BRCA1 and BRCA2 mutations and the risk for colorectal cancer.
Clin Genet. 87:411–418. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Xie F and Wang S: Clinical practice
guideline of BRCA1/2 testing for patients with breast cancer:
Chinese society of breast surgery (CSBrS) practice guideline 2021.
Chin Med J (Engl). 134:1516–1518. 2021. View Article : Google Scholar : PubMed/NCBI
|
